Synthon Announces Successful Outcomes from the Open-label Extension of the Phase III GATE Study of Synthons Glatiramer Acetate
Synthon announces that data from the open-label extension of the Phase III GATE study of the company’s generic glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS) demonstrate that efficacy, safety and tolerability were maintained over the entire 2-year study period. The data further support the safety of switching from Copaxone to Synthon’s glatiramer acetate.
Following the 9-month double-blinded period of the GATE study, in which 796 patients were treated with Synthon’s generic glatiramer acetate (GTR), Copaxone or placebo, patients initially treated with Synthon GTR continued their treatment for an additional 15 months to complete the planned 2-year study period.
Patients from the Copaxone and placebo groups were successfully switched over to treatment with Synthon GTR for a 15-month period. Results from this part of the study confirmed continued efficacy, measured by MRI parameters and clinical relapses, as well as the continued safety and tolerability during a two-year treatment period with Synthon GTR.
The data further support the safety of switching active therapy from Copaxone to Synthon’s generic glatiramer acetate. Efficacy, safety and tolerability profiles remained unaffected throughout the duration of the extension study.
Synthon announced results from the GATE study in March 2014 demonstrating that Synthon’s glatiramer acetate had an efficacy and safety profile that was equivalent to Copaxone®. The open-label data will provide further support for the evaluation of Synthon’s glatiramer acetate by regulatory authorities, prescribing neurologists and payers.
Synthon’s CEO Jacques Lemmens said: “With 8 years of thorough research work and over EUR 100 million invested in the development of our glatiramer acetate, we have clearly established equivalence, in both pre-clinical and clinical studies.”
“The open-label results constitute the last piece of the puzzle, which demonstrates equivalence in efficacy and safety, and a safe switch from Copaxone to our glatiramer acetate.”
“The MS community is in need of affordable medication. Synthon’s glatiramer acetate is the only clinically validated alternative with two years of safety and efficacy data, and could provide an affordable, efficacious and safe alternative not only for Copaxone, but also for other first-line treatments such as interferons and orals. This would allow for substantial savings on MS medication for patients and payers, without losing out on efficacy and safety.”
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance